Sanofi’s voluntary withdrawal of Dengvaxia leaves the US without an approved dengue vaccine as dengue cases in the Americas surge and the threat of more widespread infections in the mainland US rises.
Key Takeaways
-
Sanofi is discontinuing Dengvaxia due to low global demand for the dengue vaccine.







